A method for producing a phospholipid-containing composition which includes 10% by weight or more of phosphatidylserine based on the whole phospholipid-containing composition, a content of a polyunsaturated fatty acid being from 10 to 40% by weight based on the total amount of constituent fatty acids, the method including the following steps (1) and (2) in this order, and the following steps (3) and (4) in this order inexpensively and stably supplies a phospholipid-containing composition which includes phosphatidylserine to which a large amount of the polyunsaturated fatty acid is bonded at the 2-position thereof. Step (1): performing an esterification reaction of a polyunsaturated fatty acid with lysophospholipid using phospholipase A2 (PLA2) to obtain phospholipid. Step (2): adjusting an activity of PLA2 in the phospholipid to 10 U/g (phospholipid) or less after the step (1). Step (3): performing a base exchange reaction of a mixture including the phospholipid and serine in the presence of phospholipase D (PLD) to form a phospholipid-containing composition which includes phosphatidylserine. Step (4): separating the composition.

The present invention relates to uses of ether phospholipids in treating and preventing various diseases, including, but not limited to, neurodegenerative or brain diseases such as Alzheimer's disease, cognitive impairment, brain fatigue, Parkinson disease, depression, anxiety disorder, insomnia and schizophrenia; metabolic syndrome such as diabetes and obesity; various infectious diseases such as viral diseases; diseases related to inflammation; heart diseases, and immune disorders. Preferably, the ether phospholipids are derived from extracting bivalves, which provides superior efficacies in treating and preventing the diseases.

Disclosed are methods of making a modified lecithin by conducting an enzymatic conversion of a naturally derived lecithin to form a modified lecithin, e.g., having an enhanced level of phosphatidylethanolamine, phosphatidylserine, or a combination thereof. Compositions prepared from the modified lecithin and use to inhibit lipid oxidation are described.

The present invention relates to extracted microbial lipids, microbial cells comprising the lipid, and extracts thereof. The present invention also relates to use of these lipids, cells and extracts in foods, feedstuffs and beverages.

Disclosed herein are compositions comprising an isolated cellulose degrading fungus. Also disclosed are culture compositions and bioreactor compositions comprising the cellulose degrading fungus. Further described herein are filtration and extraction devices comprising the cellulose degrading fungus. Still further disclosed are bioprocessing facilities for and methods for producing co-products resulting from one or more bioprocesses of the cellulose degrading fungus.

[PROBLEM TO BE SOLVED] To provide a method for producing ether phospholipids of high purity by an easy process. [SOLUTION] This production method comprises: (A) a step of extracting total lipids from organisms with non-polar organic solvent and branched alcohol mixture; and (B) a step of reacting the total lipids obtained by the step (A) with phospholipase A1 to decompose mixed diacyl-glycerophospholipids. This makes it possible to produce plasmalogen-type glycerophospholipids or ether phospholipids of high purity by an easy process.

The present invention provides compositions comprising microbial biomass, and food products, beverage products or feedstuffs comprising microbial biomass. Described herein are the uses of said compositions and food products, beverage products or feedstuffs for producing food-like aromas and/or flavours when heated, in particular for undergoing Maillard reactions. Also provided are methods for producing food-like aromas and/or flavours.

Engineered phospholipase D mutants are described herein. Also described herein are methods of making engineered phospholipase D mutants. Additionally, methods of using engineered phospholipase D mutants are described.

Engineered phospholipase D mutants are described herein. Also described herein are methods of making engineered phospholipase D mutants. Additionally, methods of using engineered phospholipase D mutants are described.

The disclosure relates to the field of specialty chemicals and methods for their synthesis. In embodiments, the disclosure provides viable bacterial cells which comprise heterologous dual 3-hydroxy-acyl-ACP dehydratase/isomerases, etc. The disclosure further provides monounsaturated fatty acid derivative molecules produced by the viable bacterial cells which are non-native to the bacterial cells. The disclosure further provides methods for the preparation and production of non-native monounsaturated fatty acid derivative molecules such as e.g., an 3-monounsaturated fatty acid derivative, an 5-monounsaturated fatty acid derivative, an 9-monounsaturated fatty acid derivative, an 11-monounsaturated fatty acid fatty acid derivative, etc.